Spotlight on Annals

Office-based eligibility for biologics and probiotic therapy for chronic urticaria


July 3, 2017

The July issue of the Annals of Allergy, Asthma and Immunology has a variety of features that should be interesting for our readers. I would like to call attention to two specific ones that I encourage you to read.

The first, authored by Enrico Heffler, MD, PhD and colleagues, sought to determine whether a point-of-service device that can provide a blood eosinophil count was accurate enough compared to a standard laboratory-based analyzer. The data suggest that the correlation between the two methodologies was very high. This could provide immediate, office based eligibility for the use of certain biologicals in patients with severe asthma requiring a qualifying blood eosinophil level.

Year in review and an updated practice parameter


January 3, 2017

Each issue of the Annals of Allergy, Asthma and Immunology offers new opportunities for learning. The January issue is full of new features and manuscripts that will fulfil learning opportunities with wide and varying interests.

Two articles in particular are worth special mention. The first is the annual Year in Review: The Best of 2016 in the Annals, authored by the editors. We carefully selected these articles based upon our perception of greatest utility to our readers. It is a succinct way for you to see the highlights of the two volumes of the Annals published in 2016, organized based upon subheadings derived from the table of contents of each issue.

Diverse clinical problems


October 3, 2016

The upcoming October issue of the Annals of Allergy, Asthma and Immunology contains a large diversity of information in multiple formats including original articles, reviews, letters and others. Two articles in particular are worthy of mention.

The first is a retrospective study by Dr. Zazzali and colleagues that looked at three of the pivotal studies for the utility of omalizumab for chronic idiopathic urticaria in terms of the effects on accompanying episodes of angioedema. The study looked at results from all three pivotal trials (ASTER I, ASTER II, GLACIAL). Results indicated that higher dose omalizumab (300mg subcutaneously every four weeks) improved the percentage of angioedema free days compared to placebo. Interestingly, most of the episodes of angioedema in all groups was successfully managed with low intensity interventions – taking antihistamines or doing nothing.